FIELD: medicine.
SUBSTANCE: to determine the indications for intravitreal injection of ciliary neurotrophic factor (CNTF) for treatment of eye visual-nerve apparatus diseases, CNTF concentration in the patients' tear fluid (TF) is determined. At CNTF concentration of less than 17 picogram/ml (pg/ml) in TF, intravitreal administration of CNTF is prescribed.
EFFECT: method allows to determine the indications for intravitreal CNTF injection for treatment of eye visual-nerve apparatus diseases by identifying CNTF concentrations in the tear fluid.
4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE INDICATIONS FOR THE INTRAVITREUM ADMINISTRATION OF THE BRAIN-DERIVED NEUROTROPHIC FACTOR FOR THE TREATMENT OF THE PRIMARY OPEN-ANGLE GLAUCOMA | 2018 |
|
RU2678095C1 |
| METHOD FOR CORRECTION OF NEUROTROPHILIC CHANGES IN PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA AFTER CORONAVIRUS INFECTION | 2023 |
|
RU2814770C1 |
| TREATMENT OF EYE DISEASES SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH MEDICATIONS THAT ELIMINATE AGING CELLS | 2018 |
|
RU2815482C2 |
| METHOD OF ESTIMATING THE EFFICIENCY OF NEURORETIN PROTECTION OF PRIMARY OPEN-ANGLE GLAUCOMA BASED ON DETERMINATION OF THE NEUROTROPHIC FACTOR OF THE BRAIN | 2018 |
|
RU2681934C1 |
| METHOD FOR DETERMINING INDICATIONS FOR ANTIANGIOGENIC THERAPY IN CASE OF SUSPICION OF WET FORM OF AGE-RELATED MACULAR DEGENERATION | 2021 |
|
RU2758662C1 |
| METHOD FOR ASSESSING THE EFFICACY OF NEURORETINOPROTECTION OF PRIMARY OPEN-ANGLE GLAUCOMA ON BASIS OF DETERMINING RATIO OF NEURAL MARKERS | 2018 |
|
RU2681654C1 |
| METHOD OF TREATING DEGENERATIVE AND DYSTROPHIC RETINAL DISEASES | 2012 |
|
RU2495669C1 |
| METHOD FOR THE DIFFERENTIAL DIAGNOSIS OF MELANOMA OF THE CHOROID OF THE CENTRAL LOCALIZATION AND THE LATE STAGE OF AGE-RELATED MACULAR DEGENERATION | 2022 |
|
RU2792554C1 |
| METHOD FOR PREDICTION OF SENILE MACULAR DEGENERATION TRANSITION FROM PREDISCIFORM TO DISCIFORM STAGE IN PATIENTS WITH HYPERTENSION | 2007 |
|
RU2348043C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF NEOVASCULAR FORM OF AMD | 2022 |
|
RU2788103C1 |
